ClinicalTrials.gg
CompletedNCT00240617Updated Oct 26, 2016

Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks

A Phase 3 interventional study of sumatriptan succinate/naproxen sodium and placebo in Migraine Disorders, sponsored by GlaxoSmithKline. Completed at 52 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-10-26.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
623
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 42 studies testing sumatriptan in Migraine Disorders — none open to participants now, none under way, none of them phase 3. Sumatriptan · Migraine Disorders.

Enrollment
5th of 42
623 · median 74
Started
2005
the only one that year
Phase 3
18 of 42
none open now
Registered
1st of 42
by date
Lead sponsor
8 of 42
GlaxoSmithKline

Among the 42 studies testing sumatriptan in Migraine Disorders, this one is the 5th largest by enrollment, is the only one that started in 2005, is one of 18 in phase 3, and was the 1st registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 341 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

None of the 42 studies testing sumatriptan in Migraine Disorders is open now. The open studies under Migraine Disorders, anywhere →

Where they have run

About sumatriptan

Sumatriptan: first FDA approval 1992 (IMITREX STATDOSE (AUTOINJECTOR)). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 42 studies testing sumatriptan in Migraine Disorders as a file.
02

Study summary

The purpose of this study is to determine the consistency of response for Treximet (formerly known as Trexima) when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.

03

Conditions studied

  • Migraine Disorders

Keywords

  • consistency of response
  • migraine
  • satisfaction
  • early intervention
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least a 6 month history of physician diagnosed migraine and typically experiences 2-6 migraine attacks per month.
  • Typically experiences moderate to severe migraine pain preceded by a mild pain phase.
  • Differentiate between mild migraine pain and other headache types.
  • Women of must be on adequate .

Exclusion criteria

Exclusion Criteria:

  • Pregnant and/or nursing mother.
  • History of cardiovascular disease.
  • Uncontrolled hypertension.
  • Basilar or Hemiplegic migraine.
  • History of stroke or (TIA).
  • History of epilepsy or treated with anti-epileptics within past 5 years.
  • Impaired hepatic or renal function.
  • History of gastrointestinal bleeding or ulceration.
  • Allergy or to Aspirin or any other NSAID.
  • Allergy or hypersensitivity to triptans.
  • Participated in an drug trial in the previous 4 weeks.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
623 participants (actual)

Study arms

  • Active comparator
    arm 1

    Treximet (sumatriptan/naproxen sodium) formerly known as TREXIMA

    Drug: sumatriptan succinate/naproxen sodium

  • Placebo comparator
    arm 2

    placebo to match

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Score on a 4 pt migraine pain scale for multiple migraine attacks

    Time frame: 2 to 24 hours

Secondary outcomes

  1. Within patient consistency of response, freedom from all migraine pain and symptoms, satisfaction, presence or absence of neck pain/discomfort, sinus pain/pressure, recurrence of head pain, safety and tolerability

    Time frame: 2 to 24 hours

07

Study locations

52 sites
  • GSK Investigational Site
    Anniston, Alabama 36207, United States
  • GSK Investigational Site
    Tuscaloosa, Alabama 35406, United States
  • GSK Investigational Site
    Mesa, Arizona 85201, United States
  • GSK Investigational Site
    Phoenix, Arizona 85032, United States
  • GSK Investigational Site
    Hot Springs, Arkansas 71913, United States
  • GSK Investigational Site
    Irvine, California 92618, United States
  • GSK Investigational Site
    Oceanside, California 92056, United States
  • GSK Investigational Site
    San Diego, California 92108, United States
  • GSK Investigational Site
    San Diego, California 92128, United States
  • GSK Investigational Site
    Boulder, Colorado 80304, United States
  • GSK Investigational Site
    Avon, Connecticut 06001, United States
  • GSK Investigational Site
    Miami, Florida 33173, United States
  • GSK Investigational Site
    Pembroke Pines, Florida 33024, United States
  • GSK Investigational Site
    South Daytona, Florida 32119, United States
  • GSK Investigational Site
    Stuart, Florida 34996, United States
  • GSK Investigational Site
    Atlanta, Georgia 30342, United States
  • GSK Investigational Site
    Decatur, Georgia 30033, United States
  • GSK Investigational Site
    Rome, Georgia 30165, United States
  • GSK Investigational Site
    Chicago, Illinois 60607, United States
  • GSK Investigational Site
    Evansville, Indiana 47712, United States
  • GSK Investigational Site
    Baton Rouge, Louisiana 70808, United States
  • GSK Investigational Site
    Ann Arbor, Michigan 48104, United States
  • GSK Investigational Site
    St. Louis Park, Minnesota 55426, United States
  • GSK Investigational Site
    St. Louis, Missouri 63141, United States
  • GSK Investigational Site
    Moorestown, New Jersey 08057, United States
  • GSK Investigational Site
    Albuquerque, New Mexico 87108, United States
  • GSK Investigational Site
    Albany, New York 12206, United States
  • GSK Investigational Site
    Bronx, New York 10467, United States
  • GSK Investigational Site
    New York, New York 10021, United States
  • GSK Investigational Site
    Plainview, New York 11803, United States
  • GSK Investigational Site
    Rochester, New York 14609, United States
  • GSK Investigational Site
    Valley Stream, New York 11580, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27599, United States
  • GSK Investigational Site
    Greensboro, North Carolina 27401, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27609, United States
  • GSK Investigational Site
    Concinnati, Ohio 45219, United States
  • GSK Investigational Site
    West Chester, Ohio 45069, United States
  • GSK Investigational Site
    Westerville, Ohio 43081, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73104, United States
  • GSK Investigational Site
    Eugene, Oregon 97401, United States
  • GSK Investigational Site
    Salem, Oregon 97301, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19114, United States
  • GSK Investigational Site
    Anderson, South Carolina 29621, United States
  • GSK Investigational Site
    Bristol, Tennessee 37620, United States
  • GSK Investigational Site
    Clarksville, Tennessee 37043, United States
  • GSK Investigational Site
    Memphis, Tennessee 38105, United States
  • GSK Investigational Site
    Fort Worth, Texas 76135, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84121, United States
  • GSK Investigational Site
    Seattle, Washington 98195, United States
  • GSK Investigational Site
    Tacoma, Washington 98405, United States
  • GSK Investigational Site
    Wenatchee, Washington 98801, United States
08

References and documents

Publications

  • Torgovnick J, Sethi NK, Arsura E. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled cross-over study. Cephalalgia. 2010 Oct;30(10):1277; author reply 1277-9. doi: 10.1177/0333102409352810. Epub 2010 May 13. No abstract available. PubMed 20855373 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005, a primary completion of Jun 2006 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2005
First posted
Oct 18, 2005
Start
Oct 2005
Primary completionActual
Jun 2006
CompletionActual
Jun 2006
Last update
Oct 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00240617
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 18, 2005
Start date
Oct 2005
Primary completion
Jun 2006
Completion
Jun 2006
Last update
Oct 26, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sumatriptan · Naproxen

Start the discussion